|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Research and development expenses | |||||
| General and administrative expenses | |||||
| Total operating loss | |||||
| Financial income, net | |||||
| Financial expenses related to SEPA | |||||
| Impairment on associate and associated loan | |||||
| Net loss | |||||
| Basic, net loss per share | |||||
| Diluted, net loss per share | |||||
| Weighted average number of shares outstanding used in computing net loss per share, basic | |||||
| Weighted average number of shares outstanding used in computing net loss per share, diluted |
Loading...
